Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Hypopituitarism
Interventions: Arimidex (Anastrozole), Placebo, Growth Hormone; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 11 Years to 18 Years · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: DHA Treatment, Placebo for DHA; Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Up to 5 Months
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 6 more

Conditions: Diabetes Mellitus, Depression
Interventions: Enhanced treatment as usual plus adherence training, Enhanced treatment as usual plus CBT-AD; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes, Ketone Body Metabolism, Ketones, Metabolism
Interventions: Ketone Ester Acute, Placebo Acute; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes (T1D)
Interventions: L. johnsonii Probiotic, Placebo Capsule; Drug
Lead sponsor: University of Florida; Other
Eligibility: 8 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Prediabetic State, Insulin Resistance, Type2 Diabetes, Stress, Adolescent Development, Family Research
Interventions: CookingMatters, Parent Education, Physical Activity, Health Education, Mindfulness-based Stress Reduction, Brief Mindfulness Intervention; Behavioral
Lead sponsor: Colorado State University; Other
Eligibility: 12 Years to 15 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Fort Collins, Colorado

Conditions: Breast Cancer, Hypercalcemia of Malignancy, Colon Cancer, Endocrine Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Metastatic Cancer, Multiple Myeloma, Parathyroid Neoplasms, Renal Cancer, Thyroid Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer
Interventions: denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 12
States / cities: Encinitas, California • New Haven, Connecticut • Salisbury, Maryland + 9 more

Conditions: Diabetes
Interventions: team-based care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parathyroid Disease
Interventions: Tissue Samples; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Aerobic Exercise Training; Other
Lead sponsor: Baltimore VA Medical Center; Federal
Eligibility: 50 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: GlucoWatch® G2™ Biographer (GW2B), Continuous Glucose Monitoring System™ (CGMS); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 6
States / cities: Stanford, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer, Colon Cancer, HEENT Cancer, Hodgkin's Disease, Kaposi's Sarcoma, Liver Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Sarcoma, Squamous Cell Carcinoma, Thyroid Cancer
Interventions: Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 582 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions: Pramlintide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions: EndoTAG-1, Gemcitabine; Drug
Lead sponsor: SynCore Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 16
States / cities: Corona, California • Atlanta, Georgia • Columbus, Georgia + 12 more

Conditions: Polycystic Ovary Syndrome
Interventions: Not listed
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 84
States / cities: Birmingham, Alabama • Coronado, California • Lancaster, California + 71 more

Conditions: Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8, Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma
Interventions: Cabozantinib, Pharmacogenomic Study, Pharmacokinetic Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes, Type 2
Interventions: Community Health Worker Diabetes Education: Print media, CHW Diabetes Education: tailored web site; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: IIM System, Insulin Lispro and/or Insulin Glargine; Device · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Little Rock, Arkansas • Walnut Creek, California • Austin, Texas + 2 more

Conditions: Secondary Hyperparathyroidism, End Stage Renal Disease
Interventions: paricalcitol injection; Drug
Lead sponsor: Abbott; Industry
Eligibility: 2 Years to 20 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 6
States / cities: Stanford, California • Miami, Florida • Buffalo, New York + 2 more

Conditions: PreDiabetes
Interventions: CGM-DPP, Control; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
Interventions: Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: NNC0114-0006, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: La Jolla, California • Northridge, California • Aurora, Colorado + 10 more

Conditions: Thyroid Cancer
Interventions: Not listed
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys

Nutritional Intervention to Prevent Diabetes

CBT for Adherence and Depression in Diabetes

Effects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function

Lactobacillus Johnsonii in Children and Adolescents With T1D

United for Health: Type 2 Diabetes Prevention in Latino Teens

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With Diabetes Mellitus (DM)

Establishment of a Parathyroid Tissue Bank

Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes

Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children

Spectroscopy With Surface Coils and Decoupling

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

Effect of Weight & Insulin Sensitivity on Reproductive Function in PCOS: Studies in Skeletal Muscle & Adipose

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

iDecide.Decido: Diabetes Medication Decision Support Study

A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.